ADAPT Study Outlines Dual Cut-Point Protocol for Plasma p-tau217

The ADAPT study validates plasma p-tau217 assays against CSF standards, outlining optimal dual cut-points for clinical ...
Nasdaq

Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early

LONDON, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III ...
Nasdaq

BioCryst Pharma Reports Positive Data From APeX-P Study In Hereditary Angioedema

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) Monday reported positive results from APeX-P study of Orladeyo in hereditary angioedema (HAE) patients aged between 2 and 12 years. APeX-P study is ...
ascopubs.org

A randomized phase III study assessing the efficacy of liquid biopsy in early diagnosis of recurrence and second malignancies in lung cancer survivors.

A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study). Background: Lung cancer survivors are highly enriched for ...
ascopubs.org

A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal ...

T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab ...